One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates

Recent iPrEx clinical trial results provided evidence that systemic preexposure prophylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially prevent rectal HIV transmission in humans. Similarly, we have previously demonstrated that systemic administration of the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Denton, Paul W., Othieno, Florence, Martinez-Torres, Francisco, Zou, Wei, Krisko, John F., Fleming, Elisa, Zein, Sima, Powell, Daniel A., Wahl, Angela, Kwak, Youn Tae, Welch, Brett D., Kay, Michael S., Payne, Deborah A., Gallay, Philippe, Appella, Ettore, Estes, Jacob D., Lu, Min, Garcia, J. Victor
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2011
Assuntos:
Vaccines and Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147928/
https://ncbi.nlm.nih.gov/pubmed/21593172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00537-11
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares